Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

An Efficacy and Safety Study of SRM003 in the Treatment of Subjects Undergoing Creation of an Arteriovenous Fistula to Facilitate Hemodialysis Access

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Shire
ClinicalTrials.gov Identifier:
NCT01806545
First received: March 5, 2013
Last updated: November 20, 2015
Last verified: November 2015
  Purpose

A study to evaluate the efficacy of SRM003 treatment versus participating sites' standard practice treatment in improving the rate of AVF maturation and use in subjects with end-stage renal disease undergoing surgery for creation of an AVF to facilitate hemodialysis access.

It is hypothesized that when placed outside the blood vessel, the seeded SRM003 gelatin matrix containing endothelial cells can provide a continuous supply of multiple growth regulatory compounds to the underlying cells within the blood vessel, while being protected from the effects of blood flow in the vessel(s) or complications resulting from being in direct contact with the point of injury.


Condition Intervention Phase
Arteriovenous Fistula
Biological: SRM003
Other: Participating Site's standard practice
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Subject)
Primary Purpose: Treatment
Official Title: A Phase 2, Single-blind, Randomized, Controlled, Multi-center Study to Evaluate the Efficacy and Safety of SRM003 (Vascugel®) in Improving the Rate of Arteriovenous Fistula Maturation and Use in Subjects Undergoing Surgery for Creation of an Arteriovenous Fistula for Hemodialysis Access

Resource links provided by NLM:


Further study details as provided by Shire:

Primary Outcome Measures:
  • Percentage of Participants With Arteriovenous Fistula (AVF) Maturation by Week 12 Visit Based on Hemodialysis or Color-flow Doppler Ultrasound (CDUS) And Vascular Access Examination [ Time Frame: 12 weeks after surgery ] [ Designated as safety issue: No ]
    Maturation based on CDUS was assessed in a continuous fashion and was defined by the following criteria: presence of bruit throughout systole and diastole at least 8 centimeters (cm) proximal to the venous anastomosis, blood flow through the outflow vein of at least 500 milliliters (ml) per minute, and a lumen diameter of the outflow vein at least 4 mm. Maturation was determined by CDUS and vascular access examination or by first use of the AVF for hemodialysis based on investigator-reported use. Participants who discontinued prior to the Week 12 visit without assessment of maturity were considered treatment failures.


Secondary Outcome Measures:
  • Percentage of Participants With AVF Maturation by Week 26 Visit Based on Hemodialysis or CDUS And Vascular Access Examination [ Time Frame: 26 weeks after surgery ] [ Designated as safety issue: No ]
    Maturation based on CDUS was assessed in a continuous fashion and was defined by the following criteria: presence of bruit throughout systole and diastole at least 8 centimeters (cm) proximal to the venous anastomosis, blood flow through the outflow vein of at least 500 milliliters (ml) per minute, and a lumen diameter of the outflow vein at least 4 mm. Maturation was determined by CDUS and vascular access examination or by first use of the AVF for hemodialysis based on investigator-reported use. Participants who discontinued prior to the Week 26 visit without assessment of maturity were considered treatment failures.

  • Time to AVF Maturation Based on Hemodialysis or CDUS and Vascular Access Examination [ Time Frame: Up to 26 weeks after surgery ] [ Designated as safety issue: No ]
    Time to AVF maturation was defined as the duration of time (in days) from the date of randomization (AVF creation) to the date of maturation, where the date of maturation corresponds to the earlier of either the date of the first use of the study AVF for hemodialysis as determined by the investigator following discussion with the participant, or the date the AVF meets all of the following 3 criteria as determined through CDUS and vascular access examination: presence of bruit throughout systole and diastole at least 8 centimeters proximal to the venous anastomosis, blood flow through the outflow vein of at least 500 milliliters (ml) per minute, and a lumen diameter of the outflow vein at least 4 mm. Participants who died, underwent a kidney transplant, or were either lost to follow-up or did not mature during the study follow-up were censored at the time of death, time of transplant, or time of last visit, respectively.

  • Percentage of Participants With Loss of Unassisted Primary Patency [ Time Frame: Up to 26 weeks after surgery ] [ Designated as safety issue: No ]
    The time to loss of unassisted primary patency (intervention--free access survival) was defined as the duration of time in days from the date of randomization (AVF creation) until the first date of (a) any intervention designed to establish, maintain, or restore patency; (b) occlusion (commonly due to thrombosis); or (c) access abandonment.

  • Percentage of Participants With Loss of Assisted Primary Patency [ Time Frame: Up to 26 weeks after surgery ] [ Designated as safety issue: No ]
    The time to loss of assisted primary patency (thrombosis--free access survival) was defined as the duration of time in days from the date of randomization (AVF creation) until the first date of (a) occlusion (commonly due to thrombosis) or (b) access abandonment.

  • Percentage of Participants With Loss of Secondary Patency [ Time Frame: Up to 26 weeks after surgery ] [ Designated as safety issue: No ]
    The time to loss of secondary patency (access survival until abandonment) was defined as the duration of time in days from the date of randomization (AVF creation) until the date of access abandonment.

  • Change From Week 1 in Average Vascular Access Lumen Diameter Using CDUS [ Time Frame: 1, 12, and 26 weeks after surgery ] [ Designated as safety issue: No ]
    B-mode lumen diameter measurements were obtained in the outflow vein as 3 separate images for each location: at 1, 3, and 5 centimeter into the vein and from the toe of the venous anastomosis. The average of lumen diameter measurements obtained at 1, 3, and 5 cm from the anastomosis was used for this endpoint.

  • Percentage of Participants With Clinical Success Based on First Use of The Study AVF For Hemodialysis [ Time Frame: 12 and 26 weeks after surgery ] [ Designated as safety issue: No ]
    Clinical success was defined as the ability to undergo hemodialysis using the AVF. The date of clinical success corresponded to the date of the first use of the study AVF for hemodialysis as determined by the investigator, following discussion with the subject. Clinical success was assessed in a continuous fashion and, once achieved, the AVF was considered a clinical success at that and all subsequent time points. The date of clinical success based on the first use of the AVF for hemodialysis was compared with the dates of each study visit (Week 12 and Week 26); for study visits occurring prior to the date of clinical success based on the first use of the AVF for hemodialysis, the subject was counted as a nonsuccess and for study visits occurring on or after the date of maturation based on the first use of the AVF for hemodialysis, the subject was counted as a success.

  • Number of Interventions to Establish, Maintain, or Restore Patency [ Time Frame: 12 and 26 weeks after surgery ] [ Designated as safety issue: No ]
    The total number of interventions to establish, maintain, or restore patency was recorded for each participant.


Enrollment: 64
Study Start Date: March 2013
Study Completion Date: October 2014
Primary Completion Date: October 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: SRM003
One time implant (2 SRM003 pieces) on surgery day. Post-surgery, up to 26 weeks follow-up for assessment of efficacy/safety.
Biological: SRM003
One time implant (2 SRM003 pieces) on surgery day.
Other Name: Allogeneic human aortic endothelial cells cultured in a gelatin matrix (Gelfoam®).
Participating Site's standard practice
Subjects will receive sites' standard practice treatment during the surgical procedure.
Other: Participating Site's standard practice
Subjects will receive sites' standard practice treatment during the surgical procedure.

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Subject must be 18 years of age or older at the time of signing and dating informed consent (no upper age limit), can be male or female.
  2. Subject who is of child bearing potential must agree to use adequate contraception for 6 months after randomization.
  3. Subject must be currently undergoing hemodialysis or anticipating the start of hemodialysis and must require a new permanent, suitable access for the AVF creation in the upper extremity.
  4. Subject must have a life expectancy of at least 26 weeks after randomization.
  5. Subject must be able to understand and be willing to complete all study requirements.

Exclusion Criteria:

  1. Subject is currently on an active organ transplant list from a deceased donor or is undergoing assessment and expects to be placed on the active organ or bone marrow transplant list within the next 26 weeks from surgery, or expects to receive a living donor organ or bone marrow within the next 26 weeks and is unwilling to change transplant list status to "hold" for 3 months after randomization.
  2. Subject has had more than 1 access placement surgery (defined as a new access, not a revision) in the target limb.
  3. Subject has medical conditions and diseases that may cause non-compliance with the protocol
  4. Subject has a known allergy to bovine/porcine products or collagen/gelatin products.
  5. Subject has a history of intravenous drug use within 6 months prior to screening
  6. Subject is morbidly obese, defined as having a body mass index >40.
  7. Pregnant or nursing woman, or plans to become pregnant during the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01806545

  Hide Study Locations
Locations
United States, Arizona
Akdhc Medical Research Services
Phoenix, Arizona, United States, 85012
Tucson Vascular Consultants
Tucson, Arizona, United States, 85745
United States, California
Ladenheim Dialysis Access Center
Fresno, California, United States, 93710
California Institute of Renal Research
La Mesa, California, United States, 91942
VA Long Beach Health Care System Pharmacy
Long Beach, California, United States, 90822
The Regents University of California Los Angeles
Los Angeles, California, United States, 90025
California Institute of Renal Research
San Diego, California, United States, 92123
University of California, San Francisco
San Francisco, California, United States, 94143
United States, Colorado
University of Colorado Denver
Aurora, Colorado, United States, 80045
United States, Connecticut
Yale University School of Medicine
New Haven, Connecticut, United States, 06520-8042
United States, Florida
Tampa General Hospital
Tampa, Florida, United States, 33606
United States, Georgia
Georgia Regents University
Augusta, Georgia, United States, 30912
United States, Illinois
Illinois Kidney Disease & Hypertension Center
Peoria, Illinois, United States, 61603
United States, Kentucky
University of Louisville
Louisville, Kentucky, United States, 40202
United States, Louisiana
Ochsner Baptist Medical Center, Clinical Trials Unit
New Orleans, Louisiana, United States, 70115
Louisiana State University Health Science Center Shreveport
Shreveport, Louisiana, United States, 71130
United States, Massachusetts
Baystate Medical Center Pharmacy
Springfield, Massachusetts, United States, 01199
United States, Michigan
Henry Ford Hospital
Detroit, Michigan, United States, 48202
Renaissance Renal Research Institute, LLC
Detroit, Michigan, United States, 48236
McLaren Northern Michigan Hospital-NISUS Research
Petoskey, Michigan, United States, 49770
Providence Hospital, Research Dept.
Southfield, Michigan, United States, 48075
United States, Missouri
Clinical Research Consultants, LLC
Kansas City, Missouri, United States, 64111
Washington University School of Medicine
St. Louis, Missouri, United States, 63110
United States, Nevada
Sierra Nevada Nephrology Consultants
Reno, Nevada, United States, 89511
United States, New York
Montefiore Medical Center
Bronx, New York, United States, 10467
United Health Services
Johnson City, New York, United States, 13790
Mount Sinai School of Medicine Lab
New York, New York, United States, 10029
United States, North Carolina
Metrolina Nephrology Associates, PA
Charlotte, North Carolina, United States, 28204
ECU Department of Nephrology and Hypertension
Greenville, North Carolina, United States, 27834
United States, North Dakota
Sanford Research/USD-Fargo
Fargo, North Dakota, United States, 58122
United States, Ohio
University of Cincinnati Physicians Company
Cincinnati, Ohio, United States, 45267
The Cleveland Clinic Foundation
Cleveland, Ohio, United States, 44195
The Ohio State University
Columbus, Ohio, United States, 43210
Toledo Hospital
Toledo, Ohio, United States, 43560
United States, Oregon
Kaiser Permanente Northwest
Milwaukie, Oregon, United States, 97267
Northwest Renal Clinic, Inc.
Portland, Oregon, United States, 97210
United States, Pennsylvania
Penn Medicine, Perelman Center for Advanced Medicine
Philadelphia, Pennsylvania, United States, 19104
Delaware Valley Nephrology and Hypertension Associates, PC
Philadelphia, Pennsylvania, United States, 19118
Temple University School of Medicine
Philadelphia, Pennsylvania, United States, 19140
United States, South Carolina
SC Nephrology & Hypertension Center, Inc.
Orangeberg, South Carolina, United States, 29118
United States, Tennessee
Erlanger Hospital Pharmacy
Chattanooga, Tennessee, United States, 37403
Nephrology Associates, P.C.
Nashville, Tennessee, United States, 37205
United States, Texas
Baylor College of Medicine ICTR
Houston, Texas, United States, 77030
United States, Vermont
Fletcher Allen Health Care Renal Service
Burlington, Vermont, United States, 05401
United States, Virginia
Sentara Vascular Specialists
Norfolk, Virginia, United States, 23507
United States, Washington
Wenatchee Valley Medical Center
Wenatchee, Washington, United States, 98801
United States, Wisconsin
University of Wisconsin
Madison, Wisconsin, United States, 53792
Sponsors and Collaborators
Shire
Investigators
Principal Investigator: Steven Steinberg California Institute of Renal Research
  More Information

Responsible Party: Shire
ClinicalTrials.gov Identifier: NCT01806545     History of Changes
Other Study ID Numbers: AVF01-SRM003 
Study First Received: March 5, 2013
Results First Received: October 16, 2015
Last Updated: November 20, 2015
Health Authority: United States: Food and Drug Administration

Keywords provided by Shire:
Arteriovenous Fistula Surgery
Vascular Injury
Hemodialysis Access

Additional relevant MeSH terms:
Fistula
Arteriovenous Fistula
Pathological Conditions, Anatomical
Arteriovenous Malformations
Vascular Malformations
Cardiovascular Abnormalities
Cardiovascular Diseases
Vascular Fistula
Vascular Diseases
Congenital Abnormalities

ClinicalTrials.gov processed this record on December 02, 2016